Loading…
Chongqing biologics developer working on monoclonal antibody drugs including a denosumab-type bone-disease biosimilar.
Chongqing biologics developer working on monoclonal antibody drugs including a denosumab-type bone-disease biosimilar.
In one line: A small Chinese biologics/biosimilar developer.
Moat: none (IP / patents). Early-stage biologics portfolio still dependent on regulatory approval and reimbursement.
Headquarters: Chongqing, China · Employees: 984
Size Chongqing Genrix Biopharmaceutical (688443.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.34B, the 1812th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥26.59 on 6 Nov 2026.
Performance Over six months the shares fell 10.2%, against -12.3% for the median peer and -16.4% for the China market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue grew 255.7% over the last twelve months (peer median +15.6%); the operating margin is -26.9% (peer median 2.9%).
Valuation It trades at 10.0× enterprise value to sales against a peer median of 6.9× (7th most expensive of 17).
Capital Return on invested capital runs 25.8 points below its cost of capital (8.2% WACC).
Next results Next results expected around 5 May 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥801M | CN¥230M | CN¥29.8M | CN¥1.18M | CN¥106,041 |
| Revenue growth | — | +673% | +2,435% | +1,009% | — |
| Gross profit | CN¥690M | CN¥149M | -CN¥50.1M | -CN¥63.3M | -CN¥54.0M |
| EBITDA | n/a | -CN¥507M | -CN¥767M | -CN¥731M | -CN¥558M |
| Net income | -CN¥209M | -CN¥536M | -CN¥797M | -CN¥801M | -CN¥576M |
| Free cash flow | -CN¥296M | -CN¥415M | -CN¥621M | -CN¥469M | -CN¥320M |
| Capital expenditure | CN¥105M | CN¥85.4M | CN¥45.3M | CN¥91.0M | CN¥146M |
| Total debt | CN¥927M | CN¥1.06B | CN¥837M | CN¥641M | CN¥782M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Chongqing Genrix Biopharmaceutical 688443.SS | $1.34B | -10% | +256% | -27% | 10.0× | n/a |
| Amgen AMGN | $249B | +40% | +9% | 36% | 7.4× | 1.8% |
| Shanghai Henlius Biotech 2696.HK | $3.41B | -37% | +33% | 12% | 3.7× | 15.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688443.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.1% | -7.5% | 3rd highest of 21 |
| 6-month return | -10.2% | -12.3% | 10th highest of 21 |
| Distance from 52-week high | -19.0% | -38.7% | 3rd highest of 21 |
| Revenue growth (TTM) | +255.7% | +15.6% | highest of 17 |
| Operating margin | -26.9% | 2.9% | 6th lowest of 17 |
| EV / Sales | 10.0× | 6.9× | 7th most expensive of 17 |
| ROIC minus cost of capital | -25.8 pp | -4.7 pp | 7th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.34B | -10% | +256% | -27% | 10.0× | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.34B | +2% | +8% | 11% | 2.1× | 0.3% | -1.3% |
| Phibro Animal Health PAHC | United States | $1.34B | -18% | +17% | 13% | 1.4× | -7.4% | +12.7% |
| Idorsia IDIA.SW | Switzerland | $1.34B | -5% | -5% | -70% | 10.7× | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $1.34B | -26% | +49% | 24% | 3.4× | -2.4% | +13.8% |
| Hanall Biopharma 009420.KS | South Korea | $1.34B | -25% | +5% | 3% | 11.2× | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.35B | +26% | +133% | 11% | 9.8× | 26.1% | +23.1% |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.32B | -6% | -29% | 3% | 2.0× | 8.5% | -5.3% |
| LB Pharmaceuticals LBRX | United States | $1.36B | +31% | n/a | n/a | n/a | n/a | n/a |
| C.Q. Pharmaceutical 000950.SZ | China | $1.32B | -12% | -3% | 1% | 0.5× | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.31B | -7% | +14% | 19% | 5.0× | 4.0% | +27.9% |
| Voronoi 310210.KS | South Korea | $1.31B | -66% | +24% | -1,947% | 417.6× | n/a | n/a |
| Mabwell (Shanghai) Bioscience 2493.HK | Hong Kong | $1.37B | -32% | +21% | -127% | 15.3× | n/a | n/a |
| Innoviva INVA | United States | $1.38B | -17% | +18% | 36% | 2.4× | -15.4% | +3.9% |
| Avalyn Pharma AVLN | United States | $1.29B | +7% | n/a | n/a | n/a | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.39B | -33% | +70% | -220% | 15.5× | n/a | n/a |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.39B | -9% | +9% | -13% | 4.9× | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.28B | +31% | n/a | n/a | n/a | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.28B | -49% | -71% | -1,368% | 617.6× | n/a | n/a |
| GH Research GHRS | United States | $1.28B | -13% | n/a | n/a | n/a | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.40B | -33% | +27% | 12% | 8.9× | n/a | n/a |